Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-12 Earnings release - Q1 2027

More about the company

Quotes

Date	Price	Change	Volume
27/07/26	JP¥247.00	+1.23%	61,000
24/07/26	JP¥244.00	-10.62%	312,900
23/07/26	JP¥273.00	+17.17%	1,068,800
22/07/26	JP¥233.00	-1.27%	42,900
21/07/26	JP¥236.00	0.00%	15,700

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Delayed Japan Exchange Other stock markets 03:01:57 27/07/2026 BST			5-day change	1st Jan Change
247.00 ^JPY	+1.23%		+4.66%	-27.35%

06-16	Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
05-31	Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI

Market Cap	6.29B 38.45M 33.77M 31.4M 28.82M 54.15M 3.7B 54.98M 373M 146M 1.82B 144M 141M	P/E 2025	49.7x	P/E 2026	-9.95x
Enterprise Value	5.39B 32.94M 28.93M 26.91M 24.69M 46.39M 3.17B 47.11M 320M 125M 1.56B 124M 121M	EV / Sales 2025	6.38x	EV / Sales 2026	33.4x
Free-Float	28.38%	Yield 2025 *	-	Yield 2026	-

06-16	Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
05-31	Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
05-31	Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million.	CI
05-15	Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026	CI
05-15	Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
02-13	Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
02-13	Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
11/05/25	Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
17/02/25	Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025	CI
20/11/24	Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025	CI
18/12/22	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022.	CI
19/09/22	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022.	CI
23/06/22	Tsubota Laboratory Incorporated has completed an IPO in the amount of Ã‘1.8048 billion.	CI

1 day	+1.23%
1 week	+4.66%
Current month	+7.86%
1 month	+10.27%
3 months	-16.27%
6 months	-23.05%
Current year	-27.35%

Tsubota Laboratory Incorporated Share Price

Stocks

4890

JP3535700003

Biotechnology & Medical Research

Valuation: Tsubota Laboratory Incorporated

Chart: Tsubota Laboratory Incorporated

Latest news : Tsubota Laboratory Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: Tsubota Laboratory Incorporated

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Manager	Title	Age	Since
Kazuo Tsubota PSD	President	71	31/01/2019
Keisuke Mitsuoka ADM	Chief Administrative Officer	-	-
Kenji Morishima CTO	Chief Tech/Sci/R&D Officer	65	31/12/2024

Director	Title	Age	Since
Kenji Morishima BRD	Director/Board Member	65	31/05/2025
Shinichi Koizumi BRD	Director/Board Member	70	31/05/2020
Kazuo Tsubota BRD	Director/Board Member	71	31/01/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/11/24	Kazuo Tsubota	Others	Founder	63,000	0.2465%
15/11/24	Kazuo Tsubota	Others	Founder	420,000	1.6434%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TSUBOTA LABORATORY INCORPORATED	+1.23%	+4.66%	-33.60%	-60.16%	38.45M
LONZA GROUP AG	+1.07%	-3.49%	-3.35%	+11.75%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+399.22%	+647.65%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+11.81%	+60.81%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+4.46%	-10.31%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+4.76%	+43.00%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+34.39%	+134.44%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	-3.43%	+9.10%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-11.36%	-34.51%	12.7B
Average	+0.32%	+1.09%	+44.77%	+89.09%	24.53B
Weighted average by Cap.	+0.48%	+0.91%	+74.40%	+138.18%

	2025	2026
Net sales	1.36B 8.29M 7.28M 6.77M 6.21M 11.67M 798M 11.85M 80.4M 31.41M 392M 31.12M 30.45M	200M 1.22M 1.07M 998K 916K 1.72M 118M 1.75M 11.85M 4.63M 57.84M 4.59M 4.49M
Net income	205M 1.25M 1.1M 1.02M 939K 1.76M 121M 1.79M 12.15M 4.75M 59.29M 4.7M 4.6M	-761M -4.65M -4.08M -3.8M -3.48M -6.55M -448M -6.65M -45.09M -17.62M -220M -17.45M -17.08M
Net Debt	-1.45B -8.85M -7.77M -7.23M -6.63M -12.46M -852M -12.65M -85.8M -33.52M -419M -33.21M -32.49M	-901M -5.5M -4.83M -4.5M -4.13M -7.75M -530M -7.87M -53.39M -20.86M -261M -20.66M -20.22M

1 week	226	288
1 month	220	288
Current year	210	478
1 year	210	478
3 years	210	635
5 years	210	1,447
10 years	210	1,447